Loading company
Apnimed, Inc.
APMD · Nasdaq · ·
$23.94+10.3%Sep 29 close
- 1M
- -19.4%
Trailing twelve months where a flow is involved, latest reported balance where it is not.
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each quarter on its own, so seasonal highs and lows are visible.
$12.08MQ2 2026-29.4%
Everything the company sold, before any costs. Each quarter on its own, so seasonal highs and lows are visible.
$125.94MQ2 2026+86.0%
What was left after every cost, including tax. Each quarter on its own, so seasonal highs and lows are visible.
32.35MQ2 2026+580.5%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each quarter on its own, so seasonal highs and lows are visible.
Everything above comes from Apnimed, Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Not reported by this filer: Cost of Revenue, Gross Profit, Interest Expense, Profit per share, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Inventory, Long-term Debt (current), Short-term Borrowings, Borrowings (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Capital Expenditures, Dividends paid, Depreciation & Amortization, Amortization of Intangibles, and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
APMD · Nasdaq · ·
$23.94+10.3%Sep 29 close